Association between serum Vitamin E concentrations and the presence of Metabolic Syndrome: A population-based cohort study

Maral Barzegar-Amini 1, 8, *, Fateme Khorramruz 2, Hamideh Ghazizadeh 2, 3, *, Reza Sahebi 3, Maryam Mobhamadi-Bajgiran 1, Hossein Mobaddes Ardabi 2, Maryam Tayefi 2, Susan Darroudi 2, Mohsen Moohebati 1, Alireza Heidari-Bakavoli 1, Akram Mobhamadi 1, Hamid Reza Sadeghnia 1, Gordon A. Ferns 7, Seyed-Javad Hoseini 6, Majid Ghayour-Mobarhan 3

1 Cardiovascular Division, Vascular Surgery Research Center, Mashhad University of Medical Sciences, Mashhad, Iran; 2 Student Research Committee, Biochemistry of Nutrition Research Center, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran; 3 International UNESCO Center for Health Related Basic Sciences and Human Nutrition, Mashhad University of Medical Sciences, Mashhad, Iran; 4 Student Research Committee, Department of New Science and Technologies, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran; 5 Norwegian Center for e-health Research, University hospital of North Norway, Tromso, Norway; 6 Department of Medical Biotechnology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran; 7 Brighton & Sussex Medical School, Division of Medical Education, Falmer, Brighton, Sussex BN1 9PH, UK; 8 Allergy Research Center, Mashhad University of Medical Sciences, Mashhad, Iran. M BA, F KH and H GH Equally contributed as first author

Abstract. Background. Metabolic syndrome (MetS) is a cluster of clinical and metabolic features that include central obesity, dyslipidemia, hypertension and impaired glucose tolerance. These features are accompanied by increased oxidative stress and impaired antioxidant defenses. Vitamin E is a major factor in the non-enzymatic antioxidant defenses. The aim of present study was to investigate the association between serum levels of vitamin E and the presence of MetS and its components in a subsample population of Mashhad stroke and heart atherosclerotic disorder (MASHAD) study.

Methods. This cross-sectional study was carried out in 128 subjects with MetS and 235 subjects without MetS. MetS was defined according to the International-Diabetes-Federation criteria. Serum levels of vitamin E were measured using the HPLC method. Anthropometric and biochemical parameters were measured using standard protocols. Results. MetS patients had significantly lower serum levels of vitamin E (Vit E), Vit E/Total cholesterol (TC), and Vit E/ (TC+triglyceride(TG)) compared to the control group (P < 0.05). Vit E/ (TG+TC) was also significantly lower in diabetics or those with elevated levels of highly sensitive C-reactive protein (hs-CRP). Additionally, there was a significant association between Vit E/ (TG + TC) and MetS (OR:0.87, 95% CI (0.78-0.96)). Conclusions. There is a significant inverse association between Vit E/ (TG + Total Cho) and the presence of MetS. Moreover, a significantly lower Vit E/ (TC+TG) was observed in subjects with more than 3 components of the MetS. The evaluation of this association in a larger population may help further confirm these findings.

Keywords: metabolic syndrome; vitamin E; oxidative stress; antioxidant vitamins.

Abbreviation

Metabolic syndrome: MetS; Mashhad stroke and heart atherosclerotic disorder: MASHAD; High pressure liquid chromatography: HPLC; Vit: Vitamin; Total cholesterol: TC; TG: Triglycerides; Fasting blood glucose: FPG; High sensitive C-reactive protein: hs-CRP; Reactive oxygen species: ROS; Systolic blood pressure: SBP; Diastolic blood pressure: DBP; Low density lipoprotein: LDL; High density lipoprotein: HDL; Na-
Introduction

Metabolic syndrome (MetS) is a cluster of metabolic abnormalities including central obesity, dyslipidemia, hypertension (HTN) and impaired glucose tolerance. It is associated with an increased risk of obesity, diabetes mellitus and cardiovascular disease (CVD) (1, 2). Several environmental and genetic factors are involved in the pathogenesis of MetS. Furthermore, increased oxidative stress has a critical role in the etiology of complications associated with MetS and may lead to the impaired angiogenesis, endothelial dysfunction and a proinflammatory and prothrombotic state in vasculature (3, 4). Oxidative stress results from an imbalance between the synthesis of reactive oxygen species (ROS) and their removal by the antioxidant defense system, as well as dietary antioxidants (e.g. beta-carotene, vitamin E, and selenium) (5).

Vitamin E comprise two major subgroup: tocopherol and tocotrienols, that each have four different isomers (α, β, γ, and δ). α-tocopherol forms over 90% of the total tocopherols in plasma (6, 7). Whilst dietary vitamin E is rich in γ-tocopherol, the major form in the plasma is α-tocopherol which is associated with several biological activities (8). Regarding the importance of fat-soluble biological antioxidant in the body, vitamin E has a significant defensive role against oxidative stress and lipid peroxidation as well as hepatic inflammation and, therefore, preventing pathological conditions which include chronic diseases such as cardiovascular disease, diabetes mellitus and cancer (9-11).

A limited number of studies have investigated the relationship between vitamin E levels and MetS, but the results have been inconsistent. Vitamin E has been proposed as a potential agent for attenuating MetS and its components. Vitamin E is also reported to have anti-obesity, anti hypercholesterolemic, anti-diabetic and anti-hypertensive properties (12-16). It is also suggested that Vitamin E could improve inflammatory status, insulin resistance, blood glucose as well as dyslipidemia. However Godala et al concluded that Vit E levels were not associated with systolic blood pressure (SBP), total cholesterol, low density lipoprotein (LDL) and triglycerides (12, 17). There are several other studies in which no association between vitamin E and MetS have been found (18-21).

Since patients with MetS have high levels of oxidative stress and impaired antioxidant defenses, also there is controversial evidence about whether antioxidants can attenuate the progression of MetS, so in the present study we aimed to investigate the association of Vitamin E with MetS and its component.

Material and Methods

Study Population

The present study population comprised 128 subjects with MetS and 235 healthy subjects without MetS. Participants were adults aged 35-65 years, and were randomly selected from Mashhad stroke and heart atherosclerotic disorder (MASHAD) study, 2010-2020 (22). The exclusion criteria were as follows: presence of any systemic diseases such as autoimmune diseases, taking medications that included: lipid-lowering and/or anti-diabetic drugs, and being pregnant or lactating. Written informed consent was obtained from eligible subjects who wished to participate in the study. This study was approved by the Medical Ethics Committee of Mashhad Medical Sciences University.

Definition of Metabolic Syndrome

In accordance with the International Diabetes Federation (IDF) criteria, MetS was defined as having central obesity (defined as waist circumference of ≥94 cm for male or ≥80 cm for female) plus any two of the following four factors:
1. Elevated TG: ≥ 150 mg/dL (1.7 mmol/L) or specific treatment for this lipid abnormality.
2. Low HDL-cholesterol: < 40 mg/dL (1.03 mmol/L) in males and < 50 mg/dL (1.29 mmol/L) in females or specific treatment for dyslipidemia.
3. Elevated systolic blood pressure (SBP) ≥130 or di-
astolic blood pressure (DBP) ≥85 mm Hg; (FPG) ≥ 100 mg/dL (5.6 mmol/L) or treatment of previously diagnosed hypertension.

4. Elevated fasting blood glucose: (FBG) ≥ 100 mg/dL (5.6 mmol/L) or previously diagnosed type 2 diabetes (22)(61).

**Anthropometric and Biochemical Measurements**

Anthropometric parameters (weight, height, waist and hip circumference) were measured using standard procedures. Body mass index (BMI) was calculated as the ratio of weight (kg) to height in square meters (m²) and BMI of 20–24·9, 25–29·9 and ≥30 kg/m² were considered as normal, over-weight and obese, respectively. The mean values of three times measurement of systolic and diastolic pressure with a 30-minute interval was recorded as blood pressure by using a standardized mercury sphygmomanometer. Fasting venous blood samples (10 mL) were collected in vacuum tubes by an expert phlebotomist after 12-14 hours overnight fasting. The serum concentration of fasting blood glucose, total cholesterol, HDL, low density lipoprotein (LDL) and TG were assessed enzymatically using commercial kits as described previously (23, 24).

**Serum Vitamin E Measurement**

Serum levels of vitamin E (α-tocopherol) were measured by HPLC using a modified method of Papas et al.(25, 26). Since Vitamin E as a fat-soluble vitamin is circulated in blood stream by lipoproteins, in order to normalize serum concentration of Vit E and correct vitamin-free lipoproteins, measured Vit E divided to total cholesterol and total cholesterol + TG(27, 28). (Thurnham, 1986 #161; Barzegar-Amini, 2019 #82)

**Statistical analyses**

All statistical analyses were performed using SPSS version 20.0 (SPSS Inc. Chicago, IL, USA). The normal distribution was determined using the Kolmogorov-Smirnov test. Based on normality, comparison of 2 independent groups were performed using t-tests or Mann-Whitney U tests and Analysis of Variance (ANOVA) and Kruskal-Wallis tests were used to compare the values among more than 2 groups. Although Bonferroni post hoc correction was assessed to determine statistical differences between healthy subjects and different combination of components of MetS. The data were expressed as mean±SD, and median (IQR) for normally and non-normally distributed variables, respectively. Logistic regression was used to assess the relationship between Vit E indices with MetS ant its components. A $p$-value < 0.05 was considered statistically significant.

**Results**

**General characteristics of the subjects**

Clinical and demographic features of participants are listed in Table 1. A total of 363 subjects, including 47% men and 53% women were recruited into this cross-sectional study. The mean value of BMI, height, weight, hip circumference, HDL, Total Cholesterol, hs.CRP and uric acid had a significant difference between male and female groups.

**Levels of Vit E indices in subjects with risk factors of CVD**

The serum levels of Vit E, Vit E/ TC and Vit E/ (TG + TC) were lower in subjects with more than 3 components of MetS compared to subjects without component (i.e. without MetS) or with 1 and/or 2 components (Table 2) while this difference was alone significant for Vit E/TC+TG. We then assessed the levels of Vit E, Vit E/ TC and Vit E/ (TG + TC) in subjects with risk factors of CVD (Table 3). Subjects with diabetes had lower levels of Vit E/ (TG + TC) than subjects without diabetes ($P= 0.03$). Moreover, there was a negative significant association between Vit E/ (TG + TC) and hs-CRP ($P<0.05$). Accordingly, neither Vit E nor Vit E/ TC had significant differences in patients with other risk factors of CVD compared with the control group (Table3).

**Association of Vit E indices with Mets**

Based on Table 4 subjects with MetS had significantly lower Vit E, Vit E/ TC and Vit E/ (TG +
Association of Vit E indices with MetS showed that by increasing 0.1 unit of serum Vit E/ (TG + TC) there was a significant decrease 13% in risk of MetS, based on univariate and multivariate regression models (OR:0.87, 95% CI (0.79-0.97) and OR:0.87, 95% CI (0.78-0.96), respectively) (P <0.05).

**Discussion**

The results of the present study showed that subjects with MetS had significantly lower serum levels of all Vit E indices including Vit E, Vit E/TC, and Vit E/(TC+TG). According to the global thresholds all our population were Vit E deficient. Moreover, we showed a negative association between the levels of Vit E/ (TG+TC) and severity of MetS according number of criteria presented. We showed Vit E/ (TG+TC) was significantly associated with high risk of MetS, elevated hs-CRP and FBS serum levels. In the recent study we showed Vit E was significantly lower in individuals with dyslipidemics (22).

In our population, the median serum α-tocopherol was 3.11 (14.38) µg/dL and 3.11 (11.93) µg/dL in male and female subjects, respectively. While it was similar to the results of Ghaffari et al. accordingly mean of se-
rum concentration of vitamin D was 4.5 µg/dL in the control group (29), Korea (reports vary from 15.14 to 44.95 µmol/L) (30), US (males: 26.86 (26.03, 27.73) and females: 27.88 (27.09, 28.70) µmol/L) (31), and even in Iran (ranging from 16.16 to 159.96 µmol/L reported in studies from different Iranian cities) (32-34). Our previous studies also proved such a low level of Vit E serum concentration in Mashhad (35, 36) but not in Surrey, UK (37). Although sex, age, and ethnicity have shown significant association with α-tocopherol levels (31), so it maybe useful to explain such a difference between our results and the others.

As a fat soluble vitamin, we should adjust Vit E values according to simultaneous lipid profile in order to have a more comprehensive insight about its adequacy and determine a common reliable threshold for this vital vitamin. There are a number of different methods for such adjustment (38-40), but in order to have more universal index for inter-literature comparisons, it is suggested to simply calculate Vit E/TC and Vit E/(TC+TG) ratios (31). Above reported great differences in plasma Vit E are also seen in our calculated ratios having 11.6 µmol/L (41), 2.22 µmol/mmol (42), and 1.59 µmol/mmol (42) as inadequacy threshold for

---

### Table 3. Levels of Vit E, Vit E/Total Cho, Vit E/(TG+Total Cho) in subjects with risk factors of CVD

| Variable                        | Vitamin E (µg/dL) | Vit E/TC (µmol/mmol) | Vit E/(TC+TG) (µmol/mmol) |
|---------------------------------|-------------------|-----------------------|---------------------------|
| **Waist Circumferences**        |                   |                       |                           |
| Normal                          | 3.11 (20.53)      | 0.03(0.006-0.14)      | 0.03(0.005-0.12)          |
| P-value                         | 0.88              | 0.83                  | 0.52                      |
| M: W.C≥94 cm                    | 3.11 (20.53)      | 0.03(0.006-0.14)      | 0.02(0.005-0.11)          |
| F: W.C≥80 cm                    | 3.11 (20.53)      | 0.03(0.006-0.14)      | 0.02(0.005-0.11)          |
| **Diabetes**                    |                   |                       |                           |
| Normal                          | 3.11 (14.30)      | 0.01(0.005-0.08)      | 0.009(0.004-0.05)         |
| P-value                         | 0.25              | 0.10                  | 0.04*                     |
| FBS≥110 (mg/dl) or diabetic history | 2.13 (11.57)  | 0.02(0.006-0.17)      | 0.02(0.004-0.11)          |
| **Hypertension**                |                   |                       |                           |
| Normal                          | 3.11 (13.56)      | 0.03(0.006-0.12)      | 0.02(0.005-0.1)           |
| SBP≥135 or DBP≥85 (mmHg)        | 3.11 (14.16)      | 0.02(0.006-0.17)      | 0.02(0.004-0.11)          |
| P-value                         | 0.90              | 0.98                  | 0.8                       |
| Normal                          | 3.11 (14.16)      | 0.02(0.006-0.17)      | 0.02(0.004-0.11)          |
| **BMI (Kg/m²)**                 |                   |                       |                           |
| Normal                          | 3.11 (14.16)      | 0.02(0.006-0.17)      | 0.02(0.004-0.11)          |
| Overweight                      | 3.11 (14.16)      | 0.02(0.006-0.17)      | 0.02(0.004-0.11)          |
| Obesity                         | 3.11 (14.16)      | 0.02(0.006-0.17)      | 0.02(0.004-0.11)          |
| P-value                         | 0.42              | 0.35                  | 0.13                      |
| ≤1                              | 4.59 (20.42)      | 0.04(0.008-0.17)      | 0.03(0.006-0.14)          |
| (1-3)                           | 3.11 (10.24)      | 0.03(0.006-0.11)      | 0.02(0.004-0.09)          |
| ≥3                              | 3.11 (10.29)      | 0.02(0.006-0.1)       | 0.01(0.004-0.08)          |
| **hs-CRP (g/dl)**               |                   |                       |                           |
| ≤1                              | 4.59 (20.42)      | 0.04(0.008-0.17)      | 0.03(0.006-0.14)          |
| (1-3)                           | 3.11 (10.24)      | 0.03(0.006-0.11)      | 0.02(0.004-0.09)          |
| ≥3                              | 3.11 (10.29)      | 0.02(0.006-0.1)       | 0.01(0.004-0.08)          |

Data were expressed as Median (Q1-Q3). BMI, Body Mass Index; hs-CRP, High-sensitivity C-reactive protein; M, Male; F, Female; FBS, Fasting Blood Sugar; SBP, Systolic Blood Pressure; DBP, Diastolic Blood Pressure. Kruskal-Wallis Test.

### Table 4. Association between serum Vit E indices and metabolic syndrome

| Variables                      | (Median (IQR)) | Model 1 | Model 2 |
|--------------------------------|----------------|---------|---------|
| Metabolic syndrome             |                |         |         |
| Yes (n=128)                    | 3.10 (5.68)    | 0.037   | 0.86 (0.68-1.09) |
| No (n=235)                     | 3.11 (18.83)   | 0.23    | 0.84 (0.66-1.06) |
| Vitamin E (µg/dL)              |                |         |         |
| 0.02 (0.07)                    | 0.016          | 0.11    | 0.95 (0.90-1.01) |
| 0.02 (0.07)                    | 0.016          | 0.11    | 0.95 (0.90-1.01) |
| Vit E/TC (µmol/mmol)           |                |         |         |
| 0.01 (0.05)                    | 0.01           | 0.01    | 0.87 (0.87-0.97) |
| 0.03 (0.13)                    | 0.01           | 0.01    | 0.87 (0.87-0.97) |

Values are expressed as Median (IQR) for non-normally distributed variables. Logistic regression was used to evaluate the Association between serum Vit E indices and Met. Model 1 presented before adjusting for confounder factors and model 2 presented after adjusting for confounder factors (sex, age and smoking).
Vit E, Vit E/TC and Vit E/(TC+TG) respectively, all our cases were deficient in Vit E. This brings up the need for further mass population epidemiologic studies with needed adjustments in this region to find out the reason for such a great gap in Vit E values.

In our study all three Vit E indices (Vit E, Vit E/TC and Vit E/ (TC+TG)) were significantly lower in MetS+ subjects. This is partly in line with a previous study done by Godala et al. in which they found lower levels of serum Vit E in MetS+ cases. Palmieri et al. also reported a similar result in regard with α-tocopherol (43). Similarly Sempértegui et al. showed a strong inverse correlation between plasma Vit E and MetS risk (44).

Increased oxidative stress in the context of MetS (due to inflammation, obesity, hyperglycemia, hypertension, and dyslipidemia) and therefore increased activity of antioxidants such as Vit E and therefore depleting its internal and external sources can explain such a finding (17, 46)(62). According to the role of adipose tissue in storing fat-soluble vitamins, the other probable theory is shifting more amount of Vit E from plasma to adipose tissue in MetS patients in whom obesity is a major component (17, 45). Another theory in regard with lower Vit E values is the impairments in both intestinal absorption of Vit E and hepatic functions caused by accompanying inflammation and oxidative stress in MetS (46).

In contrary, a number of previous studies showed different findings. In Taiwan, Yen et al. showed significantly higher plasma α-tocopherol levels in MetS+ cases, but no significant differences in Vit E/TG ratios. They reported higher levels of TG in MetS+ cases, that was suggested high TG is a reason for higher Vit E levels in MetS+ cases, a theory which may well explain non-significant difference in Vit E/TG ratios (47). To support their finding, they have also provided dietary results in which MetS+ cases had significantly higher intake of Vit E that did not remain significant after normalizing for their fat intake (48). Higher Vit E in MetS may also be the outcome of increased need for antioxidant defense against MetS+ components. Some studies reported higher levels of Vit E concentrations in MetS+ subjects, a relationship which did not remained significant after adjusting Vit E values for TG and cholesterol; such a finding can be explained by the apparently higher levels TG and TC in MetS cases (47, 49).

A recent and interesting study that measured α-tocopherol catabolites in urine proposed another explanation for higher Vit E concentrations in MetS+ patients; higher levels of plasma lipids in MetS cases contributes to the slower α-tocopherol turnover and therefore an unrealistically higher Vit E measures in plasma (50).

Results from The Third National Health and Nutrition Examination Survey (NHANES) are also notable in which despite lower levels of several antioxidants, both Vit E and Vit E/TC levels were significantly higher in MetS+ group (51). After adjusting the data for intake of vitamins, minerals, fruits, and vegetables the results completely reversed and showed a significantly lower levels of Vit E in MetS+ subject. Serum Vit E was positively associated with MetS in NHANES study, an association which remained significant but became negative after adjusting for TG and cholesterol levels (51). Similar to our results, it can be explained by increasing antioxidant turn over in the context of oxidative condition of MetS.

One probable factor that may affect plasma levels of Vit E is dietary intake. Although Al-Daghri et al. observed significantly lower dietary intake of Vit E in MetS+ cases (52), it is not a consistent finding in all studies; for example, Wei et al. and beydoun et al. both found no associations between Vit E intake and MetS that were similar to our findings (49, 53).

After grouping the subjects according to the number of MetS criteria they have and studying Vit E indices in each group, we showed a significantly decreasing trend only in Vit E/(TC+TG) amounts, in other words, Vit E/(TC+TG) was negatively associated with the number of MetS criteria (table 3). Other similar investigations did not show consistent results. Ford et al. reported a significant positive association between both Vit E and Vit E/TC values and the number of MetS criteria (51). Beydoun et al. also in a dose-response model, showed a direct relationship between Vit E levels and MetS criteria count (54).

Analyzing the serum concentrations Vit E indices in cases with or without MetS risk factors including Waist Circumferences, Diabetes, Hypertension, Dyslipidemia, BMI, and hs-CRP only Vit E/(TC+TG)
was significantly different between groups; in other words, diabetics, and cases with elevated hs.CRP values had significantly lower Vit E/(TC+TG) ratios. Beydoun et al. found a significant positive association between Vit E and Hypertriglyceridemia but not low HDL-c, high blood pressure, Hyperglycemia, abdominal obesity, and elevated CRP (54). Faure et al. showed a significant association between Vit E and both serum cholesterol and triglycerides (55). In a study done by Garcia et al Vit E was positively associated with BMI only before adjusting for lipids (56). Contrary to this, Wallström et al. despite reporting a significant association between Vit E and central adiposity parameters (waist circumference and waist-to-hip ratio), could not show a generalized association between Vit E and BMI (57). There are not a common consensus in regard with Vit E anthropometric and biochemical associations yet (58).

Conclusion

To our knowledge this is the first study that investigates the association of Vit E, Vit E/TC, and Vit E/(TC+TG) levels with independent and accumulative MetS criteria in this region. Besides finding a great gap between Vit E concentration in our subjects and global thresholds (nearly all our cases were Vit E deficient), we showed a significant inverse association between all Vit E indices and metabolic syndrome. Moreover a significant decline in Vit E/(TC+TG) was observed in subjects with more than 3 components of the MetS. These brings up the need for more comprehensive clinical trials to examine the effectivity of Vit E supplementation in prophylaxis and treatment of MetS especially in Vit E-deficient populations and societies with high prevalence of MetS. Previous studies (59) have been done on societies with less Vit E inadequacy but there are still a gap for such studies in developing countries with high Vit E deficiency rates.

Acknowledgements: We would like to thank Mashhad University of Medical Sciences Research Council for financial supports

Conflict of interest: Each author declares that he or she has no commercial associations (e.g. consultancies, stock ownership, equity interest, patent/licensing arrangement etc.) that might pose a conflict of interest in connection with the submitted article.

Ethics approval and consent to participate

The approval number from the constituted review board, the Ethics Committee of Mashhad University of Medical Sciences (MUMS) is IR.MUMS.MEDICAL.REC.1386.250.

Availability of data and materials: Data sharing not applicable to this article as no datasets were generated or analyzed during the current study.

Funding: This work was supported by a grant (Majid Ghayour Mobarhan) from Mashhad University of Medical Science (MUMS), Iran.

Authors’ Contributions: We declare that the Authors contributed significantly towards the research study i.e., (a) conception, design and/or analysis and interpretation of data and to (b) drafting the article or revising it critically for important intellectual content and on (c) final approval of the version to be published.

References

1. Ford ES, Li C, Zhao G. Prevalence and correlates of metabolic syndrome based on a harmonious definition among adults in the US. J diabetes. 2010;2(3):180-93.
2. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Circulation. 2005;112(17):2735-52.
3. Mirhafez SR, Pasdar A, Avan A, Esmaily H, Moezzi A, Mohabati M, et al. Cytokine and growth factor profiling in patients with the metabolic syndrome. Br. J. Nutr. 2015 Jun 28;113(12):1911-9. PubMed PMID: 25990566. Epub 2015/05/21. eng.
4. Naziroglu M, Simsek M, Simsek H, Aydilek N, Ozcan Z, Atilgan R. The effects of hormone replacement therapy combined with vitamins C and E on antioxidants levels and lipid profiles in postmenopausal women with Type 2 diabetes. Clin Chim Acta. 2004 Jun;344(1-2):63-71. PubMed PMID: 15149872. Epub 2004/05/20. eng.
5. Jones DP, Go YM. Redox compartmentalization and cellular stress. Diabetes Obes Metab. 2010 Oct;12 Suppl 2:116-25. PubMed PMID: 21029308. PubMed Central PMCID: PMC3052693. Epub 2010/11/05. eng.
6. Sauberlich HE. Laboratory tests for the assessment of nutritional status: CRC press; 1999.
7. Jiang Q, Natural forms of vitamin E: metabolism, antioxidant, and anti-inflammatory activities and their role in disease prevention and therapy. Free Radic. Biol. Med. 2014;72:76-90.
8. Al-Baharna AA, Greaves RF. Fat-Soluble Vitamins: Clinical Indications and Current Challenges for Chromatographic Measurement. Clin Biochem Rev. 2016 Feb;37(1):27-47. PubMed PMID: 27057076. Pubmed Central PMCID: PMC4810759. Epub 2016/04/09. eng.

9. Byers T, Perry G. Dietary carotenoids, vitamin C, and vitamin E as protective antioxidants in human cancers. Annu. Rev. Nutr. 1992;12(1):139-59.

10. Diaz MN, Frei B, Vita JA, Keaney Jr. Antioxidants and atherosclerotic heart disease. New Eng J Med. 1997;337(6):408-16.

11. Hickman I, Macdonald G. Is vitamin E beneficial in chronic liver disease? J. Hepatol. 2007;46(2):288-90.

12. Wong SK, Chin K-Y, Suhaimi FH, Ahmad F, Ima-Nirwana S. Vitamin E As a Potential Interventionsal Treatment for Metabolic Syndrome: Evidence from Animal and Human Studies. FRONT PHARMACOL. 2017;8:444.

13. Zhao L, Kang I, Fang X, Wang W, Lee M, Hollins R, et al. Gamma-tocotrienol attenuates high-fat diet-induced obesity and insulin resistance by inhibiting adipose inflammation and M1 macrophage recruitment. Int J Obes. 2015;39(4):438.

14. Zaiden N, Ong S, Nesaretnam K, Shiba S. Gamma delta tocotrienols reduce hepatic triglyceride synthesis and VLDL secretion. J. Atheroscler. Thromb. 2010;17(10):1019-32.

15. Zaiden N, Ong S, Nesaretnam K, Shiba S. Gamma delta tocotrienols reduce hepatic triglyceride synthesis and VLDL secretion. J. Atheroscler. Thromb. 2010;17(10):1019-32.

16. Al-Baharna AA, Greaves RF. Fat-Soluble Vitamins: Clinical Indications and Current Challenges for Chromatographic Measurement. Clin Biochem Rev. 2016 Feb;37(1):27-47. PubMed PMID: 27057076. Pubmed Central PMCID: PMC4810759. Epub 2016/04/09. eng.

17. Bruscato NM, da Costa Vieira JL, do Nascimento NMR, Canto MEP, Stobbe JC, Gottlieb MG, et al. Dietary intake is not associated to the metabolic syndrome in elderly women. N Am J Med Sci. 2010;2(4):182.

18. Alberti G, Zimmet P, Shaw J, Grundy SM. The IDF consensus worldwide definition of the metabolic syndrome. Brussels: IDF. 2006;23(5):469-80.

19. Bruscato NM, da Costa Vieira JL, do Nascimento NMR, Canto MEP, Stobbe JC, Gottlieb MG, et al. Dietary intake is not associated to the metabolic syndrome in elderly women. N Am J Med Sci. 2010;2(4):182.

20. Alberti G, Zimmet P, Shaw J, Grundy SM. The IDF consensus worldwide definition of the metabolic syndrome. Brussels: IDF. 2006;23(5):469-80.

21. Bruscato NM, da Costa Vieira JL, do Nascimento NMR, Canto MEP, Stobbe JC, Gottlieb MG, et al. Dietary intake is not associated to the metabolic syndrome in elderly women. N Am J Med Sci. 2010;2(4):182.

22. Alberti G, Zimmet P, Shaw J, Grundy SM. The IDF consensus worldwide definition of the metabolic syndrome. Brussels: IDF. 2006;23(5):469-80.
2009;55(4):309-16.
34. Hekmat K, Bagheri R, Abedi P, Tabesh H. The relationship of fat soluble antioxidants with gestational diabetes in Iran: a case–control study. J Matern Fetal Neonatal Med. 2014 2014/11/01;27(16):1676-9.
35. Mohammadi A, Sadeghnia HR, Saberi-Karimian M, Safarian H, Ferns GA, Gayhour-Mobarhan M, et al. Effects of Curcumin on Serum Vitamin E Concentrations in Individuals with Metabolic Syndrome. Phytother Res. 2017;31(4):657-62.
36. Tavallae S, Zobeiri M, Haghighat-Khazaez Z, Hassanzadeh-Khayyat M, Nassiri H, Maleakeh-Nikouei B, et al. Serum vitamin E concentration in Iranian population with angiography defined coronary artery disease. Asian Biomed. 2012;6(1):19-25.
37. Gayhour-Mobarhan M, Sahebkar AH, Starkey B, Livingstone C, Wang T, Lamb D, et al. An investigation of the relationship between serum vitamin E status and coronary risk factors in dyslipidemic patients. Iran. J. Basic Med. Sci. 2008;10(4):206-15.
38. Gross M, Yu X, Hannan P, Prouty C, Jacobs JDR. Lipid standardization of serum fat-soluble antioxidant concentrations: the YALTA study. Am. J. Clin. Nutr. 2003;77(2):458-66.
39. Thurnham DI, Davies JA, Crump BJ, Situnayake RD, Davis M. The Use of Different Lipids to Express Serum Tocopherol: Lipid Ratios for the Measurement of Vitamin E Status. Ann. Clin. Biochem.1986;23(5):514-20. PubMed PMID: 3767286.
40. Horwitt MK, Harvey CC, Dahm CH, Jr., Searcy MT. Relationship between tocopherol and serum lipid levels for determination of nutritional adequacy. ANN NY ACAD SCI. 1972 Dec 18;203:223-36. PubMed PMID: 4633111. Epub 1972/12/18. eng.
41. Mahan LK, Raymond JL. Krause’s Food & the Nutrition Care Process - E-Book: Elsevier Health Sciences; 2016.
42. Thurnham DI, Davies JA, Crump BJ, Situnayake RD, Davis M. The use of different lipids to express serum tocopherol: lipid ratios for the measurement of vitamin E status. Ann Clin Biochem. 1986 Sep;23 ( Pt 5):514-20. PubMed PMID: 3767286. Epub 1986/09/01. eng.
43. Palmieri VO, Grattaglione I, Portincasa P, Palasciano G. Systemic Oxidative Alterations Are Associated with Visceral Adiposity and Liver Steatosis in Patients with Metabolic Syndrome. J Nutr. 2006;136(12):3022-6.
44. Sempérguez F, Estrella B, Tucker KL, Hamer DH, Narvaez X, Sempérguez M, et al. Metabolic syndrome in the elderly living in marginal peri-urban communities in Quito, Ecuador. Public Health Nutr. 2010;14(5):758-67. Epub 10/19.
45. Bieri JG, Evarts RP. Effect of Plasma Lipid Levels and Obesity on Tissue Stores of α-Tocopherol. Proceedings of the Society for Experimental Biology and Medicine. 1975 1975/06/01;149(2):500-2.
46. Mah E, Sapper TN, Chitchumroonchokchai C, Failla ML, Schill KE, Clinton SK, et al. α-Tocopherol bioavailability is lower in adults with metabolic syndrome regardless of dairy fat co-ingestion: a randomized, double-blind, crossover trial. Am. J. Clin. Nutr. 2015 10/0707/01/received08/31/ accepted;102(5):1070-80. PubMed PMID: PMC4625597.
47. Yen C-H, Yang N-C, Lee B-J, Lin J-Y, Hsia S, Lin P-T. The Antioxidant Status and Concentrations of Coenzyme Q10 and Vitamin E in Metabolic Syndrome. Sci. World J. 2013 09/0307/01/received07/31/accepted;2013:767968. PubMed PMID: PMC3776387.
48. Kim S, Song Y, Lee JE, Jun S, Shin S, Wie G-A, et al. Total Antioxidant Capacity from Dietary Supplement Decreases the Likelihood of Having Metabolic Syndrome in Korean Adults. Nutrients. 2017 09/22/07/24/received09/15/accepted;9(9):1055. PubMed PMID: PMC5691672.
49. Beydoun MA, Canas JA, Beydoun HA, Chen X, Shroff MR, Zonderman AB. Serum Antioxidant Concentrations and Metabolic Syndrome Are Associated among U.S. Adolescents in Recent National Surveys. J Nutr. 2012 07/1802/27/ received05/08/revised06/04/accepted;142(9):1693-704. PubMed PMID: PMC3417831.
50. Traber MG, Mah E, Leonard SW, Bobe G, Bruno RS. Metabolic syndrome increases dietary α-tocopherol requirements as assessed using urinary and plasma vitamin E catabolites: a double-blind, crossover clinical trial. Am. J. Clin. Nutr. 2017 01/1105/16/received12/02/accepted;105(3):571-9. PubMed PMID: PMC5320409.
51. Ford ES, Mokdad AH, Giles WH, Brown DW. The Metabolic Syndrome and Antioxidant Concentrations. Findings From the Third National Health and Nutrition Examination Survey. 2003;52(9):2346-52.
52. Al-Daghri N, Khan N, Alkhafy K, Al-Attas O, Alaokil M, Alfawaz H, et al. Selected Dietary Nutrients and the Prevalence of Metabolic Syndrome in Adult Males and Females in Saudi Arabia: A Pilot Study. Nutrients. 2013;5(11):4587. PubMed PMID: doi:10.3390/nu5114587.
53. Wei J, Zeng C, Gong Q-y, Li X-x, Lei G-h, Yang T-b. Associations between Dietary Antioxidant Intake and Metabolic Syndrome. PLoS ONE. 2015 06/22 11/21/received05/26/ accepted;10(6):e0130876. PubMed PMID: PMC4476578.
54. Beydoun MA, Shroff MR, Chen X, Beydoun HA, Wang Y, Zonderman AB. Serum Antioxidant Status Is Associated with Metabolic Syndrome among U.S. Adults in Recent National Surveys. J Nutr. 2011 03/3012/08/received12/26/revised01/31/accepted;141(5):903-13. PubMed PMID: PMC3077890.
55. Faure H, Preziosi P, Roussel AM, Bertrais S, Galan P, Hercberg S, et al. Factors influencing blood concentration of retinol, α-tocopherol, vitamin C, and β-carotene in the French participants of the S.U.V.I.MAX trial. Eur. J. Clin. Nutr. 2006 01/04/online;60:706.
56. Garcia OP, Ronquillo D, Caamaño Mdel C, Camacho M, Long KZ, Rosado JL, Zinc, vitamin A, and vitamin C status are associated with leptin concentrations and obesity in Mexican women: results from a cross-sectional study. Nutr. Metab. 2012 Jun 15;9(1):59. PubMed PMID: 22703731. Pubmed Central PMCID: Pmc306981. Epub 2012/06/19. eng.
57. Wallström P, Wirfält E, Lahmann PH, Gullberg B, Janzon L, Berghund G. Serum concentrations of β-carotene and α-tocopherol are associated with diet, smoking, and general and central adiposity. Am. J. Clin. Nutr. 2001;73(4):777-85.

58. Waniek S, di Giuseppe R, Plachta-Danielzik S, Ratjen I, Jacobs G, Koch M, et al. Association of Vitamin E Levels with Metabolic Syndrome, and MRI-Derived Body Fat Volumes and Liver Fat Content. Nutrients. 2017 10/1807/21/received10/11/accepted;9(10):1143. PubMed PMID: PMC5691759.

59. Czernichow S, Vergnaud A-C, Galan P, Arnaud J, Favier A, Faure H, et al. Effects of long-term antioxidant supplementation and association of serum antioxidant concentrations with risk of metabolic syndrome in adults. Am. J. Clin. Nutr. 2009;90(2):329-35.